# Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

> **NCT02195180** · PHASE2 · COMPLETED · sponsor: **ERYtech Pharma** · enrollment: 141 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma Metastatic

## Interventions

- **DRUG:** ERY001
- **DRUG:** Gemcitabine
- **DRUG:** 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)

## Key facts

- **NCT ID:** NCT02195180
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2017-02
- **Final completion:** 2017-11
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2018-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195180, "Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02195180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*